Document is current
Any future updates will be listed below
-
Authors
Yamazoe, Masahiro
Ting, Kenneth K. Y.
Lee, I-Hsiu https://orcid.org/0000-0001-7200-7867
Bapat, Aneesh https://orcid.org/0000-0002-1996-522X
Lewis, Andrew
Xiao, Ling https://orcid.org/0000-0002-5463-5576
Pulous, Fadi E. https://orcid.org/0000-0002-0794-8078
Mentkowski, Kyle https://orcid.org/0000-0002-6623-2096
Paccalet, Alexandre
Momin, Noor https://orcid.org/0000-0003-3145-6089
Seung, Hana https://orcid.org/0009-0004-7754-787X
Dolejsi, Theresa
Kumowski, Nina
Schloss, Maximilian J.
Iwamoto, Yoshiko
Ramos, Gustavo https://orcid.org/0000-0001-9582-2725
Chan, Kenneth
Antoniades, Charalambos
Casadei, Barbara https://orcid.org/0000-0002-6801-1617
Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
Ellinor, Patrick T. https://orcid.org/0000-0002-2067-0533
Naxerova, Kamila https://orcid.org/0000-0001-7744-5110
Pabel, Steffen https://orcid.org/0009-0000-1121-4889
Hulsmans, Maarten https://orcid.org/0000-0003-1009-658X
Nahrendorf, Matthias https://orcid.org/0000-0002-4021-1887
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL176359)
- License Information
-
More Information
Article History
Received: 9 February 2024
Accepted: 28 August 2025
First Online: 8 October 2025
Competing interests
: P.T.E. receives funds or material research support from Bayer AG, IBM Research, Bristol Myers Squibb, Pfizer, MyoKardia and Novartis. M.N. has received funds or material research support from Alnylam, Biotronik, CSL Behring, GlycoMimetics, GSK, Medtronic, Novartis and Pfizer, as well as consulting fees from Biogen, Gimv, IFM Therapeutics, Molecular Imaging, Sigilon, Verseau Therapeutics and Bitterroot. S.P. is employed by the Novartis Institute of Biomedical Research. The other authors declare no competing interests.
